JP2010539993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539993A5 JP2010539993A5 JP2010528876A JP2010528876A JP2010539993A5 JP 2010539993 A5 JP2010539993 A5 JP 2010539993A5 JP 2010528876 A JP2010528876 A JP 2010528876A JP 2010528876 A JP2010528876 A JP 2010528876A JP 2010539993 A5 JP2010539993 A5 JP 2010539993A5
- Authority
- JP
- Japan
- Prior art keywords
- transcription factor
- vector
- protein
- vitro
- dendritic cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims 24
- 108091023040 Transcription factor Proteins 0.000 claims 23
- 102000040945 Transcription factor Human genes 0.000 claims 23
- 210000004443 dendritic cell Anatomy 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 238000000338 in vitro Methods 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 102000013462 Interleukin-12 Human genes 0.000 claims 11
- 108010065805 Interleukin-12 Proteins 0.000 claims 11
- 229940117681 interleukin-12 Drugs 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 10
- 230000001419 dependent effect Effects 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 108010057988 ecdysone receptor Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000004568 DNA-binding Effects 0.000 claims 1
- 241000710188 Encephalomyocarditis virus Species 0.000 claims 1
- 108010001515 Galectin 4 Proteins 0.000 claims 1
- 102100039556 Galectin-4 Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 102100033159 Transcription factor 19 Human genes 0.000 claims 1
- 101710119700 Transcription factor 19 Proteins 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97822407P | 2007-10-08 | 2007-10-08 | |
| US97839407P | 2007-10-08 | 2007-10-08 | |
| US97850907P | 2007-10-09 | 2007-10-09 | |
| US97948007P | 2007-10-12 | 2007-10-12 | |
| US97948507P | 2007-10-12 | 2007-10-12 | |
| US99016707P | 2007-11-26 | 2007-11-26 | |
| US99068907P | 2007-11-28 | 2007-11-28 | |
| US99180707P | 2007-12-03 | 2007-12-03 | |
| US1908908P | 2008-01-04 | 2008-01-04 | |
| PCT/US2008/011563 WO2009048560A1 (en) | 2007-10-08 | 2008-10-08 | Engineered dendritic cells and uses for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250257A Division JP5934776B2 (ja) | 2007-10-08 | 2014-12-10 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010539993A JP2010539993A (ja) | 2010-12-24 |
| JP2010539993A5 true JP2010539993A5 (enExample) | 2011-12-22 |
Family
ID=40549463
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528876A Withdrawn JP2010539993A (ja) | 2007-10-08 | 2008-10-08 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| JP2014250257A Expired - Fee Related JP5934776B2 (ja) | 2007-10-08 | 2014-12-10 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| JP2016004584A Expired - Fee Related JP6290270B2 (ja) | 2007-10-08 | 2016-01-13 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250257A Expired - Fee Related JP5934776B2 (ja) | 2007-10-08 | 2014-12-10 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| JP2016004584A Expired - Fee Related JP6290270B2 (ja) | 2007-10-08 | 2016-01-13 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20090123441A1 (enExample) |
| EP (2) | EP2674483B1 (enExample) |
| JP (3) | JP2010539993A (enExample) |
| KR (3) | KR101740205B1 (enExample) |
| CN (1) | CN101883845B (enExample) |
| AU (1) | AU2008311292B9 (enExample) |
| BR (1) | BRPI0818287A2 (enExample) |
| CA (1) | CA2702058A1 (enExample) |
| ES (2) | ES2636460T3 (enExample) |
| HU (2) | HUE035406T2 (enExample) |
| IL (1) | IL204841A (enExample) |
| MX (1) | MX2010003720A (enExample) |
| NZ (1) | NZ585190A (enExample) |
| RU (3) | RU2484132C2 (enExample) |
| WO (1) | WO2009048560A1 (enExample) |
| ZA (1) | ZA201003163B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101835908A (zh) * | 2007-08-23 | 2010-09-15 | 英特瑞克斯顿股份有限公司 | 诊断疾病的方法和组合物 |
| JP2010540534A (ja) | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
| ES2636460T3 (es) * | 2007-10-08 | 2017-10-05 | Intrexon Corporation | Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer |
| EP2356219A4 (en) | 2008-10-08 | 2017-07-05 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
| PL2534242T3 (pl) * | 2010-02-10 | 2016-11-30 | Polepszona kompozycja do hamowania proliferacji komórek nowotworowych | |
| KR20180108886A (ko) * | 2010-03-23 | 2018-10-04 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
| WO2011127129A1 (en) * | 2010-04-06 | 2011-10-13 | Holaday John W | Methods of treating cancer |
| CN102026031B (zh) * | 2010-12-28 | 2013-09-04 | 张朝晖 | 一种机顶盒 |
| CN102174479B (zh) * | 2011-03-02 | 2013-04-03 | 北京锤特生物科技有限公司 | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 |
| US9402919B2 (en) * | 2011-03-04 | 2016-08-02 | Intrexon Corporation | Vectors conditionally expressing protein |
| KR102256613B1 (ko) | 2011-09-08 | 2021-05-27 | 프레시전 인코포레이티드 | 결정성 디아실하이드라진 및 이의 용도 |
| EP2766035B1 (en) * | 2011-10-11 | 2018-03-28 | Universität Zürich Prorektorat MNW | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| WO2013148649A1 (en) | 2012-03-26 | 2013-10-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of survivin antagonists in polyomavirus-related disease |
| SG10201901057UA (en) * | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| ES2853823T3 (es) * | 2014-09-30 | 2021-09-17 | Intervet Int Bv | Anticuerpos de PD-L1 que se unen a PD-L1 canino |
| EP3347373A1 (en) | 2015-10-10 | 2018-07-18 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| CA3004742A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| WO2017214333A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
| WO2018132494A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| CA3052446A1 (en) * | 2017-02-02 | 2018-08-09 | The Scripps Research Institute | Engineered cells and methods of use |
| AU2018222735B2 (en) * | 2017-02-17 | 2023-04-27 | George Todaro | Use of TGF alpha for the treatment of diseases and disorders |
| RU2645957C1 (ru) * | 2017-04-10 | 2018-02-28 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения лучевых повреждений мочевого пузыря |
| IL270990B2 (en) | 2017-06-07 | 2024-02-01 | Precigen Inc | Expression of new cell markers |
| RU2663468C1 (ru) * | 2017-09-25 | 2018-08-06 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы |
| WO2019173465A1 (en) | 2018-03-06 | 2019-09-12 | Intrexon Corporation | Human papillomavirus vaccines and uses of the same |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| WO2019246111A1 (en) * | 2018-06-19 | 2019-12-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand |
| US20210395773A1 (en) * | 2018-06-27 | 2021-12-23 | Precigen, Inc. | In vivo controlled combination therapy for treatment of cancer |
| US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
| WO2020206056A1 (en) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides and methods of plant protection |
| CN110804594B (zh) * | 2019-11-21 | 2020-11-20 | 启辰生生物科技(珠海)有限公司 | 工程化抗原递呈细胞及其在用于活化cd3+免疫细胞中的应用 |
| WO2021102287A1 (en) * | 2019-11-22 | 2021-05-27 | Ziopharm Oncology, Inc. | Methods of treating glioblastoma |
| MX2022011423A (es) * | 2020-03-16 | 2022-11-09 | Univ Brussel Vrije | Una mezcla de arnm para mejorar la potencia de células dendríticas. |
| CA3229251A1 (en) * | 2021-08-16 | 2023-02-23 | Aaron RING | Interleukin-12 variants and methods of use |
| CN114480280B (zh) * | 2022-03-02 | 2023-09-29 | 中国科学院理化技术研究所 | 烟草花叶病毒在刺激巨噬细胞极化为m1型巨噬细胞中应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
| FR2593630B1 (fr) | 1986-01-27 | 1988-03-18 | Maurice Francois | Ecran d'affichage a matrice active a resistance de drain et procedes de fabrication de cet ecran |
| US5225443A (en) * | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
| US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| CA2043775A1 (en) | 1990-06-14 | 1991-12-15 | Dat P. Le | Dibenzoylakylcyanohydrazines |
| IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
| US6013836A (en) * | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
| US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5814618A (en) * | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5834441A (en) * | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
| US6652850B1 (en) * | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
| WO1995014091A2 (en) * | 1993-11-18 | 1995-05-26 | Chiron Viagene, Inc. | Compositions and methods for utilizing conditionally lethal genes |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| US5573764A (en) * | 1994-01-21 | 1996-11-12 | Genetics Institute, Inc. | Use of interleukin-12 to prevent graft versus host disease |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US6306649B1 (en) * | 1995-06-27 | 2001-10-23 | Ariad Gene Therapeutics, Inc. | Heterologous transcription factors |
| US7176186B1 (en) * | 1997-09-16 | 2007-02-13 | The University Of Pittsburgh Of The Commonwealth System Of Higher Education | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization |
| US6734014B1 (en) | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
| US6723531B2 (en) * | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US5922685A (en) * | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
| AU725090B2 (en) * | 1996-06-14 | 2000-10-05 | Bayer Corporation | T-cell selective interleukin-4 agonists |
| AU6908998A (en) * | 1996-10-29 | 1998-05-22 | Baylor College Of Medicine | Modified glucocorticoid receptors, glucocorticoid receptors/progesterone receptors hybrids |
| EP0968284B1 (en) * | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| US6899870B1 (en) * | 1998-03-11 | 2005-05-31 | Board Of Regents, The University Of Texas System | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| US7279565B2 (en) * | 1998-05-05 | 2007-10-09 | Richard Voellmy | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| US6342596B1 (en) * | 1998-05-05 | 2002-01-29 | Hsf Pharmaceuticals S.A. | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US6258603B1 (en) * | 1998-06-17 | 2001-07-10 | Rohm And Haas Company | Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US6482405B1 (en) * | 1998-09-15 | 2002-11-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | In situ injection of antigen-presenting cells with genetically enhanced cytokine expression |
| CA2372181C (en) * | 1999-05-13 | 2012-04-17 | American Cyanamid Company | Adjuvant combination formulations |
| US6630324B1 (en) * | 1999-07-29 | 2003-10-07 | Baylor College Of Medicine | Aldehyde reductase bidirectional promoter and its use |
| US6774226B1 (en) * | 1999-11-30 | 2004-08-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| US20040033600A1 (en) * | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| ATE338135T1 (de) | 2000-03-22 | 2006-09-15 | Rheogene Holdings Inc | Induziertes genexpressionssystem basierend auf ecdysonrezeptoren |
| RU2192263C2 (ru) * | 2000-08-17 | 2002-11-10 | Российский научно-исследовательский нейрохирургический институт им. проф. А.Л.Поленова | Способ лечения злокачественных опухолей головного мозга |
| AR030382A1 (es) * | 2000-08-18 | 2003-08-20 | Yamanouchi Pharma Tech Inc | Formulacion oral de un inhibidor de ciclooxigenasa-2 de fusion rapida |
| US8105825B2 (en) * | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| CA2438119C (en) * | 2001-02-20 | 2014-12-16 | Rheogene Holdings, Inc. | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
| WO2002066612A2 (en) * | 2001-02-20 | 2002-08-29 | Rheogene, Inc. | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| ATE545705T1 (de) | 2001-02-20 | 2012-03-15 | Intrexon Corp | Neues induzierbares genexpressionssystem auf ecdysonrezeptor/invertebraten-retinoid-x-rezept r-basis |
| ES2390070T3 (es) | 2001-02-20 | 2012-11-06 | Intrexon Corporation | Nuevos receptores mutantes de sustitución y su uso en un sistema de expresión génica inducible basado en receptores nucleares |
| CA2349506C (en) * | 2001-06-14 | 2009-12-08 | Duke University | A method for selective expression of therapeutic genes by hyperthermia |
| US7375093B2 (en) * | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US20080050808A1 (en) | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
| US7785871B2 (en) | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| JP2006505280A (ja) * | 2002-11-07 | 2006-02-16 | チャン・ルン−ジ | 改変樹状細胞 |
| GB0228465D0 (en) * | 2002-12-06 | 2003-01-08 | Univ Belfast | A method of treating disease |
| US7304161B2 (en) * | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7456315B2 (en) * | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US20070059828A1 (en) * | 2003-11-07 | 2007-03-15 | Tetsuji Yamaoka | Carrier for nucleic acid molecule delivery |
| US20050130306A1 (en) * | 2003-12-10 | 2005-06-16 | Richard Voellmy | Viral vectors whose replication and, optionally, passenger gene are controlled by a gene switch activated by heat in the presence or absence of a small molecule regulator |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| ES2603062T3 (es) | 2004-05-18 | 2017-02-23 | Intrexon Corporation | Métodos de ensamblaje dinámico de vectores para la clonación de ADN de vectores plasmídicos |
| US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
| US7833754B2 (en) * | 2006-01-13 | 2010-11-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IL-12 for expression in mammalian cell |
| JP5881291B2 (ja) * | 2007-05-29 | 2016-03-09 | イントレキソン コーポレーション | エクジソン受容体複合体を通して外因性遺伝子の発現を調節するためのキラルジアシルヒドラジンリガンド |
| JP2010540534A (ja) * | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
| ES2636460T3 (es) * | 2007-10-08 | 2017-10-05 | Intrexon Corporation | Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer |
-
2008
- 2008-10-08 ES ES13175597.7T patent/ES2636460T3/es active Active
- 2008-10-08 HU HUE13175597A patent/HUE035406T2/en unknown
- 2008-10-08 JP JP2010528876A patent/JP2010539993A/ja not_active Withdrawn
- 2008-10-08 KR KR1020167010116A patent/KR101740205B1/ko not_active Expired - Fee Related
- 2008-10-08 AU AU2008311292A patent/AU2008311292B9/en not_active Ceased
- 2008-10-08 CA CA2702058A patent/CA2702058A1/en not_active Abandoned
- 2008-10-08 KR KR1020107010283A patent/KR101655487B1/ko not_active Expired - Fee Related
- 2008-10-08 MX MX2010003720A patent/MX2010003720A/es active IP Right Grant
- 2008-10-08 US US12/247,738 patent/US20090123441A1/en not_active Abandoned
- 2008-10-08 NZ NZ585190A patent/NZ585190A/xx not_active IP Right Cessation
- 2008-10-08 EP EP13175597.7A patent/EP2674483B1/en not_active Not-in-force
- 2008-10-08 WO PCT/US2008/011563 patent/WO2009048560A1/en not_active Ceased
- 2008-10-08 HU HUE08836827A patent/HUE024479T2/en unknown
- 2008-10-08 EP EP08836827.9A patent/EP2207874B1/en not_active Not-in-force
- 2008-10-08 KR KR1020177013507A patent/KR101932027B1/ko not_active Expired - Fee Related
- 2008-10-08 BR BRPI0818287A patent/BRPI0818287A2/pt not_active Application Discontinuation
- 2008-10-08 ES ES08836827.9T patent/ES2531522T3/es active Active
- 2008-10-08 RU RU2010118428/10A patent/RU2484132C2/ru active
- 2008-10-08 CN CN200880119203.5A patent/CN101883845B/zh not_active Expired - Fee Related
-
2010
- 2010-04-06 IL IL204841A patent/IL204841A/en active IP Right Grant
- 2010-05-05 ZA ZA2010/03163A patent/ZA201003163B/en unknown
-
2011
- 2011-09-01 US US13/224,091 patent/US20120114620A1/en not_active Abandoned
-
2013
- 2013-01-09 US US13/737,316 patent/US9675642B2/en active Active
- 2013-02-15 RU RU2013106702A patent/RU2644210C2/ru not_active IP Right Cessation
-
2014
- 2014-12-10 JP JP2014250257A patent/JP5934776B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-13 JP JP2016004584A patent/JP6290270B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-10 US US15/591,468 patent/US20170312315A1/en not_active Abandoned
- 2017-12-28 RU RU2017146770A patent/RU2711606C2/ru active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539993A5 (enExample) | ||
| RU2013106702A (ru) | Модифицированные дендритные клетки и их применение в лечении злокачественных опухолей | |
| Barczak et al. | Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response | |
| JP6686008B2 (ja) | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 | |
| JP2020532291A5 (enExample) | ||
| Foltz et al. | NCR1 expression identifies canine natural killer cell subsets with phenotypic similarity to human natural killer cells | |
| DE50313004D1 (de) | An MHC-Moleküle bindende Tumor-assoziierte Peptide | |
| JP2006515749A5 (enExample) | ||
| WO2008140621A3 (en) | Transgenic oncolytic viruses and uses thereof | |
| JP2020535845A5 (enExample) | ||
| Dunker et al. | Expression and regulation of non‐classical HLA‐G in renal cell carcinoma | |
| KR20170027669A (ko) | ＩＬ12 및 ｓｈＶＥＧＦ 동시발현 아데노바이러스를 포함하는 항종양 면역성 증진 조성물 | |
| JP2015504071A5 (enExample) | ||
| JP2006505266A (ja) | 幹細胞の増幅因子 | |
| Ikarashi et al. | Effects of human adipose tissue-derived and umbilical cord tissue-derived mesenchymal stem cells in a dextran sulfate sodium-induced mouse model | |
| MX2022011805A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix. | |
| CN114729320A (zh) | 用于将细胞重新程序化为能够呈递抗原的树突细胞2型的组合物、方法及其用途 | |
| Kurtulus et al. | Bim controls IL-15 availability and limits engagement of multiple BH3-only proteins | |
| CN111971394A (zh) | 嵌合抗原受体的肿瘤环境特异性表达 | |
| Feichtinger et al. | Constitutive and inducible co-expression systems for non-viral osteoinductive gene therapy | |
| JP2006511212A5 (enExample) | ||
| DK1760153T3 (da) | Adenovirus-/alfavirus-hybridvektor til effektiv administrering og expression af terapeutiske gener i tumorceller | |
| JPWO2021226151A5 (enExample) | ||
| Ojo et al. | Gfi1 controls the formation of effector-like CD8+ T cells during chronic infection and cancer | |
| Liang et al. | Construction of eukaryotic expression vector of TSLC1 gene |